Mundipharma to run ophthalmology portfolio distribution for NTC in Middle East and Africa

Mundipharma has expanded its ophthalmology portfolio in the Middle East and Africa by signing a new commercial partnership with NTC – an Italian pharmaceutical company with deep experience in research and development – to license and distribute a range of ophthalmic medicines in the region.

NTC’s portfolio was developed to address unmet medical needs in the treatment of several ophthalmic diseases, including blepharitis, dry eye, allergies and glaucoma.

"The addition of the NTC medicines complements Mundipharma’s current ophthalmology portfolio in the Middle East and Africa," said Mundipharma CEO, Raman Singh. "It’s another bold and important step in our efforts to establish market leadership in the region backed by a strong and diversified portfolio of medicines."

As well as licensing and distribution rights, under the partnership Mundipharma will also benefit from NTC’s commitment to research and development in ophthalmology.

NTC operates an international ophthalmology research and development programme called Italian Innovation. Through the programme, it engages with a large number of opinion leaders and clinical centres to focus on developing novel therapeutic solutions with rich clinical insights, to offer the scientific community tangible therapeutic evidence to unleash better and more affordable therapeutic treatments for patients.

"As NTC’s strategic partner in Middle East and Africa, Mundipharma can now leverage its world class development and clinical programs to improve clinical outcomes in ophthalmology," added Singh. "This is a great result for patients, who will benefit from improved access to more medicines with higher therapeutic value."

"Partnering with a leading company like Mundipharma is of real value and importance to NTC as it confirms the importance of our development efforts in the ophthalmic area," said Riccardo Carbucicchio, President and CEO, NTC.

"Mundipharma is an ideal strategic partner in the Middle East and Africa with the capability and expertise to extend the reach of these medicines to benefit more patients," he added.